Why BGPT?
logo

The Evidence Layer for Scientific AI

Ask questions across claims linked to experiments, exact results, limitations, and sources.Know what falsifiable science actually supports before you trust the answer.

Press Enter ↡ to search evidence


     Long Explanation



    Evidence Base and Design

    This 1998 single-centre observational study at Royal Melbourne Hospital compared antibody responses to influenza vaccination in three groups: 20 healthy controls, 25 renal transplant recipients on prednisolone/cyclosporine/azathioprine (PCA), and 13 recipients on prednisolone/cyclosporine/MMF (PCM), using blinded haemagglutination assays on a single vaccine batch .

    The effect is largest for A/H1N1 (post-vaccination PCM vs PCA p=0.0007; vs control p<0.0001) and is corroborated by a second clinical endpoint: 76% of PCM patients (10/13) failed a β‰₯4-fold rise to any antigen, versus 36% (9/25) for PCA and 25% (5/20) for controls .

    Critical Appraisal

    Strengths: Blinded serology, a single vaccine batch, three complementary endpoints (fold-rise, protective-titre conversion, GMT), baseline equivalence between transplant groups, and internal consistency with mechanistic plausibility (MMF blocks de novo purine synthesis, relatively lymphocyte-specific) .

    Blindspots and confounders: Non-randomized, unmatched group allocation (PCM patients came from the Tricontinental trial; PCA largely did not); age differed across groups (48.0 vs 35.6 years), and age independently reduces vaccine response β€” the authors assert this is unlikely to matter without formal adjustment. The PCM group (n=13) is small, yielding low power, which the authors themselves concede for the influenza B analysis. Pre-vaccination titres were lower in immunosuppressed groups (e.g., A/H1N1 β‰₯40 in 40% control vs 7.6% PCM), creating ceiling/floor effects. Drug exposure timing and trough MPA levels were not measured, so dose–response inference is absent .

    Interpretation caution: The design cannot isolate MMF from possible allocation differences; the authors' proposed application to antibody-mediated disease (SLE, IgA nephropathy) rests on two cited case reports plus mechanistic inference β€” conjecture, not demonstrated causal benefit. The claim that MMF patients are not at greater infection risk "thus far" relies on trials not powered for that endpoint, an omission-bias risk. Downstream literature indirectly supports broader utility: MMF later proved superior to cyclophosphamide for lupus nephritis remission (RR 1.72, 95% CI 1.17–2.55) .

    Bottom Line

    The central finding β€” MMF profoundly suppresses the vaccine antibody response in humans in vivo β€” is well-supported for influenza A antigens and is mechanistically coherent, but the modest, non-randomized sample and unmeasured confounders (age, MPA exposure) temper causal certainty; a randomized, MPA-monitored vaccine-response trial would be the decisive test.



    Feedback:    

    Updated: November 17, 2026

     BGPT Paper Review



    Study Novelty

    70%

    First in-vivo human demonstration that MMF preferentially suppresses antibody production over conventional regimens; the concept existed in animals/in vitro but human confirmation was new in 1998.



    Scientific Quality

    70%

    Rigorous blinded serology with three converging endpoints, but non-randomized allocation, n=13 in the MMF arm, unadjusted age confounding, and no MPA pharmacokinetic data limit causal strength.



    Study Generality

    60%

    Findings generalize conceptually to antibody-mediated disease and vaccine strategy, but were demonstrated only for influenza in one centre's renal transplant cohort.



    Study Usefulness

    80%

    Directly informed immunization timing (vaccinate pre-transplant), ring vaccination of contacts, and rationale for MMF in antibody-mediated diseases later validated in lupus nephritis trials.



    Study Reproducibility

    60%

    Methods (vaccine batch, standard HIA, statistical tests) are clearly reported, but exact subject-level data, MMF trough levels, and randomization are unavailable for exact replication.



    Explanatory Depth

    60%

    Mechanistic link to IMPDH/purine inhibition is plausible and cited, but the paper does not measure B-cell counts, IMPDH activity, or drug levels, leaving the mechanism inferential.


    🎁 Authors: Collect 169 Free Science Tokens (β‰ˆ $16.9 USD)

    Claim My Author Tokens

    Use for 42 days of free BGPT access (4 tokens = 1 day) or trade/sell (β‰ˆ $16.9 USD)

     Top Data Sources ExportMCP



     DataGen



    Generated scientific data; not direct experimental measurements.

     Hypothesis Graveyard



    MMF's humoral suppression is merely a by-product of T-cell help suppression: refuted by the paper's own cited in-vitro data showing T-independent polyclonal B-cell responses are nearly ablated.


    Cyclosporine alone explains the reduced vaccine response in PCM: rejected by the within-study comparison, since both transplant arms received identical cyclosporine dosing yet PCM responses were far lower.

     Science Art


    Paper Review: Suppression of the humoral immune response by mycophenolate mofetil Science Art

     Science Movie



    Make a narrated HD Science movie for this answer ($64 per minute)




     Discussion


    Stay current without chasing every paper.

    Know what changed, what holds up, and what remains uncertain. Every Friday. No ads.


    My BGPT